{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:19:09Z","timestamp":1792718349088,"version":"4.5.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T00:00:00Z","timestamp":1436313600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00281-015-0511-7","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T12:50:05Z","timestamp":1436273405000},"page":"543-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Cytokines in the immunopathology of systemic sclerosis"],"prefix":"10.1007","volume":"37","author":[{"given":"Jasmin","family":"Raja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Paul","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,8]]},"reference":[{"issue":"Suppl 1","key":"511_CR1","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1002\/eji.200737772","volume":"37","author":"CA Dinarello","year":"2007","unstructured":"Dinarello CA (2007) Historical insights into cytokines. Eur J Immunol 37(Suppl 1):S34\u2013S45","journal-title":"Eur J Immunol"},{"key":"511_CR2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/eci.11.40","volume":"7","author":"MR York","year":"2011","unstructured":"York MR (2011) Novel insights on the role of the innate immune system in systemic sclerosis. Expert Rev Clin Immunol 7:481\u2013489","journal-title":"Expert Rev Clin Immunol"},{"key":"511_CR3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","volume":"124","author":"S Akira","year":"2006","unstructured":"Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783\u2013801","journal-title":"Cell"},{"key":"511_CR4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrrheum.2009.136","volume":"5","author":"R Baccala","year":"2009","unstructured":"Baccala R, Gonzalez-Quintial R, Lawson BR, Stern ME, Kono DH, Beutler B, Theofilopoulos AN (2009) Sensors of the innate immune system: their mode of action. Nat Rev Rheumatol 5:448\u2013456","journal-title":"Nat Rev Rheumatol"},{"key":"511_CR5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.autrev.2010.09.015","volume":"10","author":"J Wei","year":"2011","unstructured":"Wei J, Bhattacharyya S, Tourtellotte WG, Varga J (2011) Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 10:267\u2013275","journal-title":"Autoimmun Rev"},{"key":"511_CR6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ajpath.2012.09.007","volume":"182","author":"S Bhattacharyya","year":"2013","unstructured":"Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, Feng G, Pope RM, Budinger GR, Mutlu GM, Lafyatis R, Radstake T, Feghali-Bostwick C, Varga J (2013) Toll-like receptor 4 signaling augments transforming growth factor-beta responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol 182:192\u2013205","journal-title":"Am J Pathol"},{"key":"511_CR7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.taap.2005.05.002","volume":"210","author":"RR Razonable","year":"2006","unstructured":"Razonable RR, Henault M, Paya CV (2006) Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines. Toxicol Appl Pharmacol 210:181\u2013189","journal-title":"Toxicol Appl Pharmacol"},{"key":"511_CR8","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/rheumatology\/kei244","volume":"45","author":"FK Tan","year":"2006","unstructured":"Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, Jin L, Arnett FC Jr (2006) Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 45:694\u2013702","journal-title":"Rheumatology (Oxford)"},{"key":"511_CR9","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1038\/jid.2010.200","volume":"130","author":"GA Farina","year":"2010","unstructured":"Farina GA, York MR, Di Marzio M, Collins CA, Meller S, Homey B, Rifkin IR, Marshak-Rothstein A, Radstake TR, Lafyatis R (2010) Poly(I:C) drives type I IFN- and TGFbeta-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol 130:2583\u20132593","journal-title":"J Invest Dermatol"},{"key":"511_CR10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/art.27224","volume":"62","author":"S Assassi","year":"2010","unstructured":"Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, McNearney TA, Chaussabel D, Oommen N, Fischbach M, Shah KR, Charles J, Pascual V, Reveille JD, Tan FK (2010) Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 62:589\u2013598","journal-title":"Arthritis Rheum"},{"key":"511_CR11","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/ard.2009.121400","volume":"69","author":"ML Eloranta","year":"2010","unstructured":"Eloranta ML, Franck-Larsson K, Lovgren T, Kalamajski S, Ronnblom A, Rubin K, Alm GV, Ronnblom L (2010) Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 69:1396\u20131402","journal-title":"Ann Rheum Dis"},{"key":"511_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/intimm\/dxh186","volume":"17","author":"K Takeda","year":"2005","unstructured":"Takeda K, Akira S (2005) Toll-like receptors in innate immunity. Int Immunol 17:1\u201314","journal-title":"Int Immunol"},{"key":"511_CR13","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/art.22382","volume":"56","author":"MR York","year":"2007","unstructured":"York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R (2007) A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists. Arthritis Rheum 56:1010\u20131020","journal-title":"Arthritis Rheum"},{"key":"511_CR14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/art.30190","volume":"63","author":"T Hugle","year":"2011","unstructured":"Hugle T, Hogan V, White KE, van Laar JM (2011) Mast cells are a source of transforming growth factor beta in systemic sclerosis. Arthritis Rheum 63:795\u2013799","journal-title":"Arthritis Rheum"},{"key":"511_CR15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11926-003-0043-3","volume":"5","author":"BL Gruber","year":"2003","unstructured":"Gruber BL (2003) Mast cells in the pathogenesis of fibrosis. Curr Rheumatol Rep 5:147\u2013153","journal-title":"Curr Rheumatol Rep"},{"key":"511_CR16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000163933","volume":"63","author":"BM Kraling","year":"1995","unstructured":"Kraling BM, Maul GG, Jimenez SA (1995) Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes\/macrophages. Pathobiology 63:48\u201356","journal-title":"Pathobiology"},{"key":"511_CR17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga J, Abraham D (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 117:557\u2013567","journal-title":"J Clin Invest"},{"key":"511_CR18","first-page":"646","volume":"23","author":"VD Steen","year":"1996","unstructured":"Steen VD, Engel EE, Charley MR, Medsger TA Jr (1996) Soluble serum interleukin 2 receptors in patients with systemic sclerosis. J Rheumatol 23:646\u2013649","journal-title":"J Rheumatol"},{"key":"511_CR19","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.4049\/jimmunol.168.7.3649","volume":"168","author":"LI Sakkas","year":"2002","unstructured":"Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD (2002) Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 168:3649\u20133659","journal-title":"J Immunol"},{"key":"511_CR20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nri1412","volume":"4","author":"TA Wynn","year":"2004","unstructured":"Wynn TA (2004) Fibrotic disease and the T(H)1\/T(H)2 paradigm. Nat Rev Immunol 4:583\u2013594","journal-title":"Nat Rev Immunol"},{"key":"511_CR21","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.4049\/jimmunol.166.5.3432","volume":"166","author":"A Wangoo","year":"2001","unstructured":"Wangoo A, Sparer T, Brown IN, Snewin VA, Janssen R, Thole J, Cook HT, Shaw RJ, Young DB (2001) Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol 166:3432\u20133439","journal-title":"J Immunol"},{"key":"511_CR22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000098208","volume":"73","author":"G Lakos","year":"2006","unstructured":"Lakos G, Melichian D, Wu M, Varga J (2006) Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 73:224\u2013237","journal-title":"Pathobiology"},{"key":"511_CR23","first-page":"1751","volume":"151","author":"C Mavalia","year":"1997","unstructured":"Mavalia C, Scaletti C, Romagnani P, Carossino AM, Pignone A, Emmi L, Pupilli C, Pizzolo G, Maggi E, Romagnani S (1997) Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 151:1751\u20131758","journal-title":"Am J Pathol"},{"key":"511_CR24","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/1529-0131(199906)42:6<1168::AID-ANR13>3.0.CO;2-L","volume":"42","author":"SP Atamas","year":"1999","unstructured":"Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, Alms WJ, White B (1999) Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 42:1168\u20131178","journal-title":"Arthritis Rheum"},{"key":"511_CR25","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/pmic.200301007","volume":"5","author":"P Rottoli","year":"2005","unstructured":"Rottoli P, Magi B, Perari MG, Liberatori S, Nikiforakis N, Bargagli E, Cianti R, Bini L, Pallini V (2005) Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 5:1423\u20131430","journal-title":"Proteomics"},{"key":"511_CR26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.1780270607","volume":"27","author":"AD Roumm","year":"1984","unstructured":"Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP (1984) Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 27:645\u2013653","journal-title":"Arthritis Rheum"},{"key":"511_CR27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/art.1780200410","volume":"20","author":"R Fleischmajer","year":"1977","unstructured":"Fleischmajer R, Perlish JS, Reeves JR (1977) Cellular infiltrates in scleroderma skin. Arthritis Rheum 20:975\u2013984","journal-title":"Arthritis Rheum"},{"key":"511_CR28","doi-asserted-by":"crossref","first-page":"12319","DOI":"10.1073\/pnas.1635114100","volume":"100","author":"ML Whitfield","year":"2003","unstructured":"Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100:12319\u201312324","journal-title":"Proc Natl Acad Sci U S A"},{"key":"511_CR29","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","volume":"50","author":"S Sato","year":"2004","unstructured":"Sato S, Fujimoto M, Hasegawa M, Takehara K (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50:1918\u20131927","journal-title":"Arthritis Rheum"},{"key":"511_CR30","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","volume":"169","author":"M Hasegawa","year":"2006","unstructured":"Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF (2006) B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169:954\u2013966","journal-title":"Am J Pathol"},{"key":"511_CR31","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI0215078","volume":"109","author":"E Saito","year":"2002","unstructured":"Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S (2002) CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109:1453\u20131462","journal-title":"J Clin Invest"},{"key":"511_CR32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.autrev.2014.07.003","volume":"13","author":"A Lanteri","year":"2014","unstructured":"Lanteri A, Sobanski V, Langlois C, Lefevre G, Hauspie C, Sanges S, Lambert M, Morell-Dubois S, Hatron PY, Hachulla E, Launay D, Dubucquoi S (2014) Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmun Rev 13:974\u2013980","journal-title":"Autoimmun Rev"},{"key":"511_CR33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","volume":"54","author":"T Matsushita","year":"2006","unstructured":"Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S (2006) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54:192\u2013201","journal-title":"Arthritis Rheum"},{"key":"511_CR34","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/art.10977","volume":"48","author":"PQ Hu","year":"2003","unstructured":"Hu PQ, Fertig N, Medsger TA Jr, Wright TM (2003) Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48:1363\u20131373","journal-title":"Arthritis Rheum"},{"key":"511_CR35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","volume":"35","author":"VD Steen","year":"2005","unstructured":"Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35:35\u201342","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"511_CR36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/1756-185X.12322","volume":"18","author":"I Sujau","year":"2015","unstructured":"Sujau I, Ng CT, Sthaneshwar P, Sockalingam S, Cheah TE, Yahya F, Jasmin R (2015) Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. Int J Rheum Dis 18(4):459\u2013465","journal-title":"Int J Rheum Dis"},{"key":"511_CR37","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar4486","volume":"16","author":"P Moinzadeh","year":"2014","unstructured":"Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP, Ong VH (2014) Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 16:R53","journal-title":"Arthritis Res Ther"},{"key":"511_CR38","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/art.27549","volume":"62","author":"AA Shah","year":"2010","unstructured":"Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L (2010) Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I\/III antibodies. Arthritis Rheum 62:2787\u20132795","journal-title":"Arthritis Rheum"},{"key":"511_CR39","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00296-009-1068-3","volume":"30","author":"S Okazaki","year":"2010","unstructured":"Okazaki S, Ogawa F, Iwata Y, Hara T, Muroi E, Komura K, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S (2010) Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis. Rheumatol Int 30:871\u2013878","journal-title":"Rheumatol Int"},{"key":"511_CR40","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.06.00152705","volume":"28","author":"MC Tamby","year":"2006","unstructured":"Tamby MC, Humbert M, Guilpain P, Servettaz A, Dupin N, Christner JJ, Simonneau G, Fermanian J, Weill B, Guillevin L, Mouthon L (2006) Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J 28:799\u2013807","journal-title":"Eur Respir J"},{"key":"511_CR41","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1164\/rccm.200707-1015OC","volume":"177","author":"B Terrier","year":"2008","unstructured":"Terrier B, Tamby MC, Camoin L, Guilpain P, Broussard C, Bussone G, Yaici A, Hotellier F, Simonneau G, Guillevin L, Humbert M, Mouthon L (2008) Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med 177:1128\u20131134","journal-title":"Am J Respir Crit Care Med"},{"key":"511_CR42","first-page":"551","volume":"26","author":"AM Salih","year":"1999","unstructured":"Salih AM, Nixon NB, Dawes PT, Mattey DL (1999) Soluble adhesion molecules and anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy. J Rheumatol 26:551\u2013555","journal-title":"J Rheumatol"},{"key":"511_CR43","first-page":"1963","volume":"30","author":"J Constans","year":"2003","unstructured":"Constans J, Dupuy R, Blann AD, Resplandy F, Seigneur M, Renard M, Longy-Boursier M, Schaeverbeke T, Guerin V, Boisseau MR, Conri C (2003) Anti-endothelial cell autoantibodies and soluble markers of endothelial cell dysfunction in systemic lupus erythematosus. J Rheumatol 30:1963\u20131966","journal-title":"J Rheumatol"},{"key":"511_CR44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1172\/JCI118377","volume":"97","author":"D Carvalho","year":"1996","unstructured":"Carvalho D, Savage CO, Black CM, Pearson JD (1996) IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 97:111\u2013119","journal-title":"J Clin Invest"},{"key":"511_CR45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D30VD8P0XW","volume":"8","author":"UF Haustein","year":"2002","unstructured":"Haustein UF (2002) Systemic sclerosis-scleroderma. Dermatol Online J 8:3","journal-title":"Dermatol Online J"},{"key":"511_CR46","first-page":"527","volume":"16","author":"A Pignone","year":"1998","unstructured":"Pignone A, Scaletti C, Matucci-Cerinic M, Vazquez-Abad D, Meroni PL, Del Papa N, Falcini F, Generini S, Rothfield N, Cagnoni M (1998) Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. Clin Exp Rheumatol 16:527\u2013532","journal-title":"Clin Exp Rheumatol"},{"key":"511_CR47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vph.2013.05.002","volume":"59","author":"SI Wolf","year":"2013","unstructured":"Wolf SI, Howat S, Abraham DJ, Pearson JD, Lawson C (2013) Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endothelial pro-inflammatory cascades. Vascul Pharmacol 59:19\u201326","journal-title":"Vascul Pharmacol"},{"key":"511_CR48","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar4457","volume":"16","author":"A Kill","year":"2014","unstructured":"Kill A, Tabeling C, Undeutsch R, Kuhl AA, Gunther J, Radic M, Becker MO, Heidecke H, Worm M, Witzenrath M, Burmester GR, Dragun D, Riemekasten G (2014) Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther 16:R29","journal-title":"Arthritis Res Ther"},{"key":"511_CR49","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar4503","volume":"16","author":"J Gunther","year":"2014","unstructured":"Gunther J, Kill A, Becker MO, Heidecke H, Rademacher J, Siegert E, Radic M, Burmester GR, Dragun D, Riemekasten G (2014) Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients. Arthritis Res Ther 16:R65","journal-title":"Arthritis Res Ther"},{"key":"511_CR50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/08830189509056712","volume":"12","author":"J Varga","year":"1995","unstructured":"Varga J, Bashey RI (1995) Regulation of connective tissue synthesis in systemic sclerosis. Int Rev Immunol 12:187\u2013199","journal-title":"Int Rev Immunol"},{"key":"511_CR51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1242\/dmm.004077","volume":"4","author":"TR Cox","year":"2011","unstructured":"Cox TR, Erler JT (2011) Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech 4:165\u2013178","journal-title":"Dis Model Mech"},{"key":"511_CR52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214:199\u2013210","journal-title":"J Pathol"},{"key":"511_CR53","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1002\/art.23074","volume":"56","author":"JH Distler","year":"2007","unstructured":"Distler JH, Jungel A, Pileckyte M, Zwerina J, Michel BA, Gay RE, Kowal-Bielecka O, Matucci-Cerinic M, Schett G, Marti HH, Gay S, Distler O (2007) Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 56:4203\u20134215","journal-title":"Arthritis Rheum"},{"key":"511_CR54","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1582-4934.2010.01027.x","volume":"14","author":"M Manetti","year":"2010","unstructured":"Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M (2010) Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 14:1241\u20131254","journal-title":"J Cell Mol Med"},{"key":"511_CR55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1755-1536-4-13","volume":"4","author":"L Morgan-Rowe","year":"2011","unstructured":"Morgan-Rowe L, Nikitorowicz J, Shiwen X, Leask A, Tsui J, Abraham D, Stratton R (2011) Thrombospondin 1 in hypoxia-conditioned media blocks the growth of human microvascular endothelial cells and is increased in systemic sclerosis tissues. Fibrogenesis Tissue Repair 4:13","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"Suppl 2","key":"511_CR56","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar2187","volume":"9","author":"AE Koch","year":"2007","unstructured":"Koch AE, Distler O (2007) Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther 9(Suppl 2):S3","journal-title":"Arthritis Res Ther"},{"key":"511_CR57","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(04)16853-0","volume":"364","author":"M Kuwana","year":"2004","unstructured":"Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y (2004) Defective vasculogenesis in systemic sclerosis. Lancet 364:603\u2013610","journal-title":"Lancet"},{"key":"511_CR58","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1002\/art.22035","volume":"54","author":"N Papa Del","year":"2006","unstructured":"Del Papa N, Quirici N, Soligo D, Scavullo C, Cortiana M, Borsotti C, Maglione W, Comina DP, Vitali C, Fraticelli P, Gabrielli A, Cortelezzi A, Lambertenghi-Deliliers G (2006) Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 54:2605\u20132615","journal-title":"Arthritis Rheum"},{"key":"511_CR59","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1586\/eci.11.39","volume":"7","author":"A Usategui","year":"2011","unstructured":"Usategui A, del Rey MJ, Pablos JL (2011) Fibroblast abnormalities in the pathogenesis of systemic sclerosis. Expert Rev Clin Immunol 7:491\u2013498","journal-title":"Expert Rev Clin Immunol"},{"key":"511_CR60","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/1529-0131(200102)44:2<474::AID-ANR67>3.0.CO;2-#","volume":"44","author":"H Ihn","year":"2001","unstructured":"Ihn H, Yamane K, Kubo M, Tamaki K (2001) Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 44:474\u2013480","journal-title":"Arthritis Rheum"},{"key":"511_CR61","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11926-005-0069-9","volume":"7","author":"H Ihn","year":"2005","unstructured":"Ihn H (2005) Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep 7:156\u2013162","journal-title":"Curr Rheumatol Rep"},{"key":"511_CR62","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1016\/j.febslet.2006.04.033","volume":"580","author":"J Massague","year":"2006","unstructured":"Massague J, Gomis RR (2006) The logic of TGFbeta signaling. FEBS Lett 580:2811\u20132820","journal-title":"FEBS Lett"},{"key":"511_CR63","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/art.11157","volume":"48","author":"Y Mori","year":"2003","unstructured":"Mori Y, Chen SJ, Varga J (2003) Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 48:1964\u20131978","journal-title":"Arthritis Rheum"},{"key":"511_CR64","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/sj.jid.5700303","volume":"126","author":"W Ishida","year":"2006","unstructured":"Ishida W, Mori Y, Lakos G, Sun L, Shan F, Bowes S, Josiah S, Lee WC, Singh J, Ling LE, Varga J (2006) Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol 126:1733\u20131744","journal-title":"J Invest Dermatol"},{"key":"511_CR65","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1073\/pnas.062010399","volume":"99","author":"C Dong","year":"2002","unstructured":"Dong C, Zhu S, Wang T, Yoon W, Li Z, Alvarez RJ, ten Dijke P, White B, Wigley FM, Goldschmidt-Clermont PJ (2002) Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A 99:3908\u20133913","journal-title":"Proc Natl Acad Sci U S A"},{"key":"511_CR66","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1242\/jcs.02554","volume":"118","author":"A Moustakas","year":"2005","unstructured":"Moustakas A, Heldin CH (2005) Non-Smad TGF-beta signals. J Cell Sci 118:3573\u20133584","journal-title":"J Cell Sci"},{"key":"511_CR67","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/exd.12256","volume":"22","author":"S Ohgo","year":"2013","unstructured":"Ohgo S, Hasegawa S, Hasebe Y, Mizutani H, Nakata S, Akamatsu H (2013) Bleomycin inhibits adipogenesis and accelerates fibrosis in the subcutaneous adipose layer through TGF-beta1. Exp Dermatol 22:769\u2013771","journal-title":"Exp Dermatol"},{"key":"511_CR68","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/1523-1747.ep12345771","volume":"106","author":"A Igarashi","year":"1996","unstructured":"Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, Grotendorst GR, Takehara K (1996) Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 106:729\u2013733","journal-title":"J Invest Dermatol"},{"key":"511_CR69","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0002-9440(10)63289-0","volume":"165","author":"G Lakos","year":"2004","unstructured":"Lakos G, Takagawa S, Chen SJ, Ferreira AM, Han G, Masuda K, Wang XJ, DiPietro LA, Varga J (2004) Targeted disruption of TGF-beta\/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 165:203\u2013217","journal-title":"Am J Pathol"},{"key":"511_CR70","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa067655","volume":"357","author":"C Fonseca","year":"2007","unstructured":"Fonseca C, Lindahl GE, Ponticos M, Sestini P, Renzoni EA, Holmes AM, Spagnolo P, Pantelidis P, Leoni P, McHugh N, Stock CJ, Shi-Wen X, Denton CP, Black CM, Welsh KI, du Bois RM, Abraham DJ (2007) A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 357:1210\u20131220","journal-title":"N Engl J Med"},{"key":"511_CR71","first-page":"1876","volume":"22","author":"A Ludwicka","year":"1995","unstructured":"Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, Leroy EC, Sutherland S, Silver RM (1995) Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 22:1876\u20131883","journal-title":"J Rheumatol"},{"key":"511_CR72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/1523-1747.ep12276895","volume":"92","author":"S Gay","year":"1989","unstructured":"Gay S, Jones RE Jr, Huang GQ, Gay RE (1989) Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 92:301\u2013303","journal-title":"J Invest Dermatol"},{"key":"511_CR73","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","volume":"354","author":"SS Baroni","year":"2006","unstructured":"Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667\u20132676","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"511_CR74","first-page":"v2-4","volume":"47","author":"M Trojanowska","year":"2008","unstructured":"Trojanowska M (2008) Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 47(Suppl 5):v2-4","journal-title":"Rheumatology (Oxford)"},{"key":"511_CR75","first-page":"328","volume":"24","author":"M Hasegawa","year":"1997","unstructured":"Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328\u2013332","journal-title":"J Rheumatol"},{"key":"511_CR76","first-page":"1252","volume":"28","author":"J Tsuji-Yamada","year":"2001","unstructured":"Tsuji-Yamada J, Nakazawa M, Minami M, Sasaki T (2001) Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis. J Rheumatol 28:1252\u20131258","journal-title":"J Rheumatol"},{"key":"511_CR77","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archderm.1996.03890310088013","volume":"132","author":"V Salmon-Ehr","year":"1996","unstructured":"Salmon-Ehr V, Serpier H, Nawrocki B, Gillery P, Clavel C, Kalis B, Birembaut P, Maquart FX (1996) Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 132:802\u2013806","journal-title":"Arch Dermatol"},{"key":"511_CR78","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/annrheumdis-2012-202814","volume":"73","author":"AL Mathes","year":"2014","unstructured":"Mathes AL, Christmann RB, Stifano G, Affandi AJ, Radstake TR, Farina GA, Padilla C, McLaughlin S, Lafyatis R (2014) Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin. Ann Rheum Dis 73:1864\u20131872","journal-title":"Ann Rheum Dis"},{"key":"511_CR79","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1006\/bbrc.1993.1024","volume":"190","author":"Y Kawaguchi","year":"1993","unstructured":"Kawaguchi Y, Harigai M, Suzuki K, Hara M, Kobayashi K, Ishizuka T, Matsuki Y, Tanaka N, Nakamura H (1993) Interleukin 1 receptor on fibroblasts from systemic sclerosis patients induces excessive functional responses to interleukin 1 beta. Biochem Biophys Res Commun 190:154\u2013161","journal-title":"Biochem Biophys Res Commun"},{"key":"511_CR80","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/annrheumdis-2011-200955","volume":"71","author":"K Khan","year":"2012","unstructured":"Khan K, Xu S, Nihtyanova S, Derrett-Smith E, Abraham D, Denton CP, Ong VH (2012) Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis. Ann Rheum Dis 71:1235\u20131242","journal-title":"Ann Rheum Dis"},{"key":"511_CR81","volume":"2","author":"S O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly S, Cant R, Ciechomska M, van Laar JM (2013) Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunol 2, e4","journal-title":"Clin Transl Immunol"},{"key":"511_CR82","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.bbrc.2008.06.054","volume":"373","author":"K Hikami","year":"2008","unstructured":"Hikami K, Ehara Y, Hasegawa M, Fujimoto M, Matsushita M, Oka T, Takehara K, Sato S, Tokunaga K, Tsuchiya N (2008) Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis. Biochem Biophys Res Commun 373:403\u2013407","journal-title":"Biochem Biophys Res Commun"},{"key":"511_CR83","doi-asserted-by":"crossref","first-page":"L914","DOI":"10.1152\/ajplung.2000.278.5.L914","volume":"278","author":"T Arai","year":"2000","unstructured":"Arai T, Abe K, Matsuoka H, Yoshida M, Mori M, Goya S, Kida H, Nishino K, Osaki T, Tachibana I, Kaneda Y, Hayashi S (2000) Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol 278:L914\u2013L922","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"511_CR84","doi-asserted-by":"crossref","first-page":"75s","DOI":"10.1111\/1523-1747.ep12874789","volume":"95","author":"RD Granstein","year":"1990","unstructured":"Granstein RD, Flotte TJ, Amento EP (1990) Interferons and collagen production. J Invest Dermatol 95:75s\u201380s","journal-title":"J Invest Dermatol"},{"key":"511_CR85","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jaci.2005.09.035","volume":"116","author":"P Romagnani","year":"2005","unstructured":"Romagnani P, Maggi L, Mazzinghi B, Cosmi L, Lasagni L, Liotta F, Lazzeri E, Angeli R, Rotondi M, Fili L, Parronchi P, Serio M, Maggi E, Romagnani S, Annunziato F (2005) CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol 116:1372\u20131379","journal-title":"J Allergy Clin Immunol"},{"key":"511_CR86","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10753-014-9848-7","volume":"37","author":"L Zhang","year":"2014","unstructured":"Zhang L, Yan JW, Wang YJ, Wan YN, Wang BX, Tao JH, Chen B, Li BZ, Yang GJ, Wang J (2014) Association of interleukin 1 family with systemic sclerosis. Inflammation 37:1213\u20131220","journal-title":"Inflammation"},{"key":"511_CR87","doi-asserted-by":"crossref","first-page":"15220","DOI":"10.1074\/jbc.275.20.15220","volume":"275","author":"DJ Abraham","year":"2000","unstructured":"Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A (2000) Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 275:15220\u201315225","journal-title":"J Biol Chem"},{"key":"511_CR88","first-page":"S40","volume":"29","author":"JH Distler","year":"2011","unstructured":"Distler JH, Jordan S, Airo P, Alegre-Sancho JJ, Allanore Y, Balbir Gurman A, Caporali R, Caramaschi P, Carreira PE, Chizzolini C, Cutolo M, Tuncay Duruoz M, Farge-Bancel D, Hesselstrand R, Iannone F, De Keyser F, Kucharz EJ, Launay D, de la Pena Garcia Lefebvre P, Lukacova O, Marasini B, Martinovic D, Marques Neto JF, Radic M, Rednic S, Riemekasten G, Rovensky J, Seidel MF, Senel S, Smith V, Sunderkotter C, Ton E, van Laar JM, Matucci-Cerinic M, Muller Ladner U, Distler O (2011) Is there a role for TNFalpha antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol 29:S40\u2013S45","journal-title":"Clin Exp Rheumatol"},{"key":"511_CR89","first-page":"514","volume":"31","author":"K Komura","year":"2004","unstructured":"Komura K, Sato S, Hasegawa M, Fujimoto M, Takehara K (2004) Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 31:514\u2013519","journal-title":"J Rheumatol"},{"key":"511_CR90","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s10067-012-2023-3","volume":"31","author":"NA Azab","year":"2012","unstructured":"Azab NA, Rady HM, Marzouk SA (2012) Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement. Clin Rheumatol 31:1359\u20131364","journal-title":"Clin Rheumatol"},{"key":"511_CR91","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1165\/ajrcmb.16.1.8998084","volume":"16","author":"N Hagimoto","year":"1997","unstructured":"Hagimoto N, Kuwano K, Nomoto Y, Kunitake R, Hara N (1997) Apoptosis and expression of Fas\/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 16:91\u2013101","journal-title":"Am J Respir Cell Mol Biol"},{"key":"511_CR92","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.4049\/jimmunol.181.10.7243","volume":"181","author":"A Mozaffarian","year":"2008","unstructured":"Mozaffarian A, Brewer AW, Trueblood ES, Luzina IG, Todd NW, Atamas SP, Arnett HA (2008) Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol 181:7243\u20137253","journal-title":"J Immunol"},{"key":"511_CR93","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/346425a0","volume":"346","author":"TA Springer","year":"1990","unstructured":"Springer TA (1990) Adhesion receptors of the immune system. Nature 346:425\u2013434","journal-title":"Nature"},{"key":"511_CR94","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/rheumatology\/34.11.1048","volume":"34","author":"CP Denton","year":"1995","unstructured":"Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM, Black CM (1995) Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 34:1048\u20131054","journal-title":"Br J Rheumatol"},{"key":"511_CR95","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/art.37712","volume":"65","author":"M Manetti","year":"2013","unstructured":"Manetti M, Guiducci S, Romano E, Rosa I, Ceccarelli C, Mello T, Milia AF, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M (2013) Differential expression of junctional adhesion molecules in different stages of systemic sclerosis. Arthritis Rheum 65:247\u2013257","journal-title":"Arthritis Rheum"},{"key":"511_CR96","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-140-2-200401200-00013","volume":"140","author":"SA Jimenez","year":"2004","unstructured":"Jimenez SA, Derk CT (2004) Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140:37\u201350","journal-title":"Ann Intern Med"},{"key":"511_CR97","doi-asserted-by":"crossref","first-page":"521958","DOI":"10.1155\/2012\/521958","volume":"2012","author":"A Dooley","year":"2012","unstructured":"Dooley A, Bruckdorfer KR, Abraham DJ (2012) Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants. Cardiol Res Pract 2012:521958","journal-title":"Cardiol Res Pract"},{"key":"511_CR98","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1002\/art.22861","volume":"56","author":"MJ Mulligan-Kehoe","year":"2007","unstructured":"Mulligan-Kehoe MJ, Drinane MC, Mollmark J, Casciola-Rosen L, Hummers LK, Hall A, Rosen A, Wigley FM, Simons M (2007) Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum 56:3448\u20133458","journal-title":"Arthritis Rheum"},{"key":"511_CR99","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/01.bor.0000138677.88694.a4","volume":"16","author":"MB Kahaleh","year":"2004","unstructured":"Kahaleh MB (2004) Raynaud phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol 16:718\u2013722","journal-title":"Curr Opin Rheumatol"},{"key":"511_CR100","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/art.22721","volume":"56","author":"L Shand","year":"2007","unstructured":"Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM, Denton CP (2007) Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 56:2422\u20132431","journal-title":"Arthritis Rheum"},{"key":"511_CR101","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-009-8191-5","volume":"40","author":"L Mouthon","year":"2011","unstructured":"Mouthon L, Berezne A, Bussone G, Noel LH, Villiger PM, Guillevin L (2011) Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. Clin Rev Allergy Immunol 40:84\u201391","journal-title":"Clin Rev Allergy Immunol"},{"key":"511_CR102","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655\u20132666","journal-title":"N Engl J Med"},{"key":"511_CR103","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962\u20133970","journal-title":"Arthritis Rheum"},{"key":"511_CR104","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/ard.2010.142000","volume":"70","author":"EN Le","year":"2011","unstructured":"Le EN, Wigley FM, Shah AA, Boin F, Hummers LK (2011) Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 70:1104\u20131107","journal-title":"Ann Rheum Dis"},{"key":"511_CR105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","volume":"133","author":"AJ Gerbino","year":"2008","unstructured":"Gerbino AJ, Goss CH, Molitor JA (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133:455\u2013460","journal-title":"Chest"},{"key":"511_CR106","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3899\/jrheum.071169","volume":"36","author":"SR Johnson","year":"2009","unstructured":"Johnson SR, Feldman BM, Pope JE, Tomlinson GA (2009) Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol 36:323\u2013329","journal-title":"J Rheumatol"},{"key":"511_CR107","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","volume":"44","author":"JE Pope","year":"2001","unstructured":"Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O\u2019Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351\u20131358","journal-title":"Arthritis Rheum"},{"key":"511_CR108","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrrheum.2013.46","volume":"9","author":"CP Denton","year":"2013","unstructured":"Denton CP, Ong VH (2013) Targeted therapies for systemic sclerosis. Nat Rev Rheumatol 9:451\u2013464","journal-title":"Nat Rev Rheumatol"},{"key":"511_CR109","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.autrev.2011.04.013","volume":"10","author":"S Bosello","year":"2011","unstructured":"Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, Ferraccioli G (2011) B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 10:624\u2013630","journal-title":"Autoimmun Rev"},{"key":"511_CR110","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","volume":"72","author":"M Elhai","year":"2013","unstructured":"Elhai M, Meunier M, Matucci-Cerinic M, Maurer B, Riemekasten G, Leturcq T, Pellerito R, Von Muhlen CA, Vacca A, Airo P, Bartoli F, Fiori G, Bokarewa M, Riccieri V, Becker M, Avouac J, Muller-Ladner U, Distler O, Allanore Y (2013) Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 72:1217\u20131220","journal-title":"Ann Rheum Dis"},{"key":"511_CR111","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/onc.2008.479","volume":"28","author":"S Bhattacharyya","year":"2009","unstructured":"Bhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, Leof E, Varga J (2009) A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 28:1285\u20131297","journal-title":"Oncogene"},{"key":"511_CR112","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/art.23698","volume":"58","author":"J Pannu","year":"2008","unstructured":"Pannu J, Asano Y, Nakerakanti S, Smith E, Jablonska S, Blaszczyk M, ten Dijke P, Trojanowska M (2008) Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 58:2528\u20132537","journal-title":"Arthritis Rheum"},{"key":"511_CR113","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","volume":"56","author":"JH Distler","year":"2007","unstructured":"Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56:311\u2013322","journal-title":"Arthritis Rheum"},{"key":"511_CR114","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","volume":"114","author":"CE Daniels","year":"2004","unstructured":"Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114:1308\u20131316","journal-title":"J Clin Invest"},{"key":"511_CR115","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/rheumatology\/ken104","volume":"47","author":"PP Sfikakis","year":"2008","unstructured":"Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM (2008) Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 47:735\u2013737","journal-title":"Rheumatology (Oxford)"},{"key":"511_CR116","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","volume":"70","author":"RF Spiera","year":"2011","unstructured":"Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK (2011) Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 70:1003\u20131009","journal-title":"Ann Rheum Dis"},{"key":"511_CR117","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/BOR.0b013e328337c3d6","volume":"22","author":"VH Ong","year":"2010","unstructured":"Ong VH, Denton CP (2010) Innovative therapies for systemic sclerosis. Curr Opin Rheumatol 22:264\u2013272","journal-title":"Curr Opin Rheumatol"},{"key":"511_CR118","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1365-2133.2007.07777.x","volume":"156","author":"H Ihn","year":"2007","unstructured":"Ihn H, Mimura Y, Yazawa N, Jinnin M, Asano Y, Yamane K, Tamaki K (2007) High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol 156:1058\u20131060","journal-title":"Br J Dermatol"},{"key":"511_CR119","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3899\/jrheum.140833","volume":"42","author":"CL Poelman","year":"2015","unstructured":"Poelman CL, Hummers LK, Wigley FM, Anderson C, Boin F, Shah AA (2015) Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol 42:236\u2013242","journal-title":"J Rheumatol"},{"key":"511_CR120","doi-asserted-by":"crossref","unstructured":"Raja J, Nihtyanova SI, Ong VH, Denton CP (2015) An observational study of intravenous immunoglobulin therapy in the treatment of gastrointestinal involvement in systemic sclerosis. Rheumatology 54(suppl 1):i161. doi: 10.1093\/rheumatology\/kev090.052","DOI":"10.1093\/rheumatology\/kev090.052"},{"key":"511_CR121","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/rheumatology\/keh600","volume":"44","author":"Y Asano","year":"2005","unstructured":"Asano Y, Ihn H, Asashima N, Yazawa N, Mimura Y, Jinnin M, Yamane K, Tamaki K (2005) A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford) 44:824\u2013826","journal-title":"Rheumatology (Oxford)"},{"key":"511_CR122","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/art.10363","volume":"46","author":"M Blank","year":"2002","unstructured":"Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O (2002) The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 46:1689\u20131690","journal-title":"Arthritis Rheum"},{"key":"511_CR123","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2147\/VHRM.S2270","volume":"4","author":"MK Steiner","year":"2008","unstructured":"Steiner MK, Preston IR (2008) Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 4:943\u2013952","journal-title":"Vasc Health Risk Manag"},{"key":"511_CR124","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/rheumatology\/keq241","volume":"49","author":"CJ Valerio","year":"2010","unstructured":"Valerio CJ, Handler CE, Kabunga P, Smith CJ, Denton CP, Coghlan JG (2010) Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. Rheumatology (Oxford) 49:2147\u20132153","journal-title":"Rheumatology (Oxford)"},{"key":"511_CR125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA Jr, Morganti A, Kramer F, Korn JH, Seibold JR (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32\u201338","journal-title":"Ann Rheum Dis"},{"key":"511_CR126","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809\u2013818","journal-title":"N Engl J Med"},{"key":"511_CR127","first-page":"2417","volume":"34","author":"DB Badesch","year":"2007","unstructured":"Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N, Simonneau G (2007) Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 34:2417\u20132422","journal-title":"J Rheumatol"},{"key":"511_CR128","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","volume":"112","author":"R Fries","year":"2005","unstructured":"Fries R, Shariat K, von Wilmowsky H, Bohm M (2005) Sildenafil in the treatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy. Circulation 112:2980\u20132985","journal-title":"Circulation"},{"key":"511_CR129","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/ard.2009.116475","volume":"69","author":"CS Brueckner","year":"2010","unstructured":"Brueckner CS, Becker MO, Kroencke T, Huscher D, Scherer HU, Worm M, Burmester G, Riemekasten G (2010) Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 69:1475\u20131478","journal-title":"Ann Rheum Dis"},{"key":"511_CR130","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","volume":"49","author":"PD Shenoy","year":"2010","unstructured":"Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, Agarwal V (2010) Efficacy of tadalafil in secondary Raynaud\u2019s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 49:2420\u20132428","journal-title":"Rheumatology (Oxford)"},{"key":"511_CR131","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2466-10-26","volume":"10","author":"S Udalov","year":"2010","unstructured":"Udalov S, Dumitrascu R, Pullamsetti SS, Al-tamari HM, Weissmann N, Ghofrani HA, Guenther A, Voswinckel R, Seeger W, Grimminger F, Schermuly RT (2010) Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulm Med 10:26","journal-title":"BMC Pulm Med"},{"key":"511_CR132","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2172-11-62","volume":"11","author":"P D\u2019Amelio","year":"2010","unstructured":"D\u2019Amelio P, Cristofaro MA, D\u2019Amico L, Veneziano L, Roato I, Sassi F, Bisignano G, Saracco M, Pellerito R, Patane S, Ferracini R, Pescarmona GP, Isaia GC (2010) Iloprost modulates the immune response in systemic sclerosis. BMC Immunol 11:62","journal-title":"BMC Immunol"},{"key":"511_CR133","first-page":"1407","volume":"19","author":"FM Wigley","year":"1992","unstructured":"Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP (1992) Intravenous iloprost treatment of Raynaud\u2019s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 19:1407\u20131414","journal-title":"J Rheumatol"},{"key":"511_CR134","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.47.1.43","volume":"47","author":"NJ McHugh","year":"1988","unstructured":"McHugh NJ, Csuka M, Watson H, Belcher G, Amadi A, Ring EF, Black CM, Maddison PJ (1988) Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud\u2019s phenomenon in systemic sclerosis. Ann Rheum Dis 47:43\u201347","journal-title":"Ann Rheum Dis"},{"key":"511_CR135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrrheum.2009.26","volume":"5","author":"J Varga","year":"2009","unstructured":"Varga J, Pasche B (2009) Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 5:200\u2013206","journal-title":"Nat Rev Rheumatol"},{"key":"511_CR136","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","volume":"56","author":"CP Denton","year":"2007","unstructured":"Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen F, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR (2007) Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192. Arthritis Rheum 56:323\u2013333","journal-title":"Arthritis Rheum"},{"key":"511_CR137","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K","volume":"43","author":"K Kurasawa","year":"2000","unstructured":"Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, Takabayashi K, Iwamoto I (2000) Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 43:2455\u20132463","journal-title":"Arthritis Rheum"},{"key":"511_CR138","first-page":"S44","volume":"30","author":"F Bandinelli","year":"2012","unstructured":"Bandinelli F, Del Rosso A, Gabrielli A, Giacomelli R, Bartoli F, Guiducci S, Matucci CM (2012) CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment. Clin Exp Rheumatol 30:S44\u2013S49","journal-title":"Clin Exp Rheumatol"},{"key":"511_CR139","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/rheumatology\/kep371","volume":"49","author":"X Shi-wen","year":"2010","unstructured":"Shi-wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ (2010) Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology (Oxford) 49:259\u2013263","journal-title":"Rheumatology (Oxford)"},{"key":"511_CR140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2353\/ajpath.2009.080574","volume":"174","author":"M Wu","year":"2009","unstructured":"Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J (2009) Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 174:519\u2013533","journal-title":"Am J Pathol"},{"key":"511_CR141","first-page":"1801","volume":"35","author":"A Abou-Raya","year":"2008","unstructured":"Abou-Raya A, Abou-Raya S, Helmii M (2008) Statins: potentially useful in therapy of systemic sclerosis-related Raynaud\u2019s phenomenon and digital ulcers. J Rheumatol 35:1801\u20131808","journal-title":"J Rheumatol"},{"key":"511_CR142","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/6b021f46-17bd-4ffe-a378-a1b8d24a1398","volume":"3","author":"JN Fleming","year":"2008","unstructured":"Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK, Molitor JA, Henstorf G, Lafyatis R, Pritchard DK, Adams LD, Furst DE, Schwartz SM (2008) Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One 3, e1452","journal-title":"PLoS One"},{"key":"511_CR143","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood-2007-02-072389","volume":"110","author":"RA Nash","year":"2007","unstructured":"Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD, Gooley TA, Holmberg L, Henstorf G, LeMaistre CF, Mayes MD, McDonagh KT, McLaughlin B, Molitor JA, Nelson JL, Shulman H, Storb R, Viganego F, Wener MH, Seibold JR, Sullivan KM, Furst DE (2007) High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 110:1388\u20131396","journal-title":"Blood"},{"key":"511_CR144","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/ard.2007.071464","volume":"67","author":"MC Vonk","year":"2008","unstructured":"Vonk MC, Marjanovic Z, van den Hoogen FH, Zohar S, Schattenberg AV, Fibbe WE, Larghero J, Gluckman E, Preijers FW, van Dijk AP, Bax JJ, Roblot P, van Riel PL, van Laar JM, Farge D (2008) Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 67:98\u2013104","journal-title":"Ann Rheum Dis"},{"key":"511_CR145","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM Laar van","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kotter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C, Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quere I, Rich E, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socie G, Gratwohl A, Tyndall A (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. Jama 311:2490\u20132498","journal-title":"Jama"},{"key":"511_CR146","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/157488811794480663","volume":"6","author":"F Milanetti","year":"2011","unstructured":"Milanetti F, Bucha J, Testori A, Burt RK (2011) Autologous hematopoietic stem cell transplantation for systemic sclerosis. Curr Stem Cell Res Ther 6:16\u201328","journal-title":"Curr Stem Cell Res Ther"},{"issue":"Suppl 1","key":"511_CR147","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1038\/sj.bmt.1704055","volume":"32","author":"RK Burt","year":"2003","unstructured":"Burt RK, Oyama Y, Traynor A, Quigley K, Brush M, Rodriguez J, Barr WG (2003) Hematopoietic stem cell transplantation for systemic sclerosis with rapid improvement in skin scores: is neoangiogenesis occurring? Bone Marrow Transplant 32(Suppl 1):S65\u2013S67","journal-title":"Bone Marrow Transplant"},{"key":"511_CR148","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(02)11976-3","volume":"360","author":"S Inaba","year":"2002","unstructured":"Inaba S, Egashira K, Komori K (2002) Peripheral-blood or bone-marrow mononuclear cells for therapeutic angiogenesis? Lancet 360:2083, author reply 2084","journal-title":"Lancet"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-015-0511-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00281-015-0511-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-015-0511-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T19:33:11Z","timestamp":1652815991000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00281-015-0511-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,8]]},"references-count":148,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["511"],"URL":"https:\/\/doi.org\/10.1007\/s00281-015-0511-7","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,8]]}}}